What is the association between warfarin therapy duration after bioprosthetic aortic valve replacement and risk of mortality, thromboembolic complications and bleeding?
A study by M rie C, K ber L, Skov Olsen P, Andersson C, Gislason G, Skov Jensen J, Torp-Pedersen C. published in JAMA in 2012, found that there is an association between warfarin therapy duration after bioprosthetic aortic valve replacement and risk of mortality, thromboembolic complications and bleeding. The study found that patients with a warfarin therapy duration of less than 3 months had a greater risk of mortality, thromboembolic complications and bleeding compared to those with a warfarin therapy duration of more than 3 months. Additionally, the study also found that patients with a warfarin therapy duration of more than 12 months had a lower risk of mortality, thromboembolic complications and bleeding compared to those with a warfarin therapy duration of less than 12 months.